By targeting the GI pathway, Gelesis has the potential to transform how related chronic diseases are treated.
* Products are investigational and have not been cleared by the FDA for use in the United States.
Other pre-clinical programs: GS400 for IBD in pre-clinical stage.
* Products are investigational and have not been cleared by the FDA for use in the United States.
Other pre-clinical programs: GS400 for IBD in pre-clinical stage.
